URI Undergraduate and Graduate Course Catalog 2003-2004

This is a digitized, downloadable version of the University of Rhode Island course catalog.https://digitalcommons.uri.edu/course-catalogs/1055/thumbnail.jp

URI Undergraduate and Graduate Course Catalog 2013-2014

This is a downloadable PDF version of the University of Rhode Island course catalog.https://digitalcommons.uri.edu/course-catalogs/1065/thumbnail.jp

University catalog, 2016-2017

The catalog is a comprehensive reference for your academic studies. It includes a list of all degree programs offered at MU, including bachelors, masters, specialists, doctorates, minors, certificates, and emphasis areas. It details the university wide requirements, the curricular requirements for each program, and in some cases provides a sample plan of study. The catalog includes a complete listing and description of approved courses. It also provides information on academic policies, contact information for supporting offices, and a complete listing of faculty members. -- Page 3

Virginia Commonwealth University Courses

Listing of courses for the 2019-2020 year

Virginia Commonwealth University Courses

Listing of courses for the 2018-2019 year

Virginia Commonwealth University Courses

Listing of courses for the 2021-2022 year

Virginia Commonwealth University Courses

Listing of courses for the 2022-2023 year

Designing a broad-spectrum integrative approach for cancer prevention and treatment

Targeted therapies and the consequent adoption of "personalized" oncology have achieved notablesuccesses in some cancers; however, significant problems remain with this approach. Many targetedtherapies are highly toxic, costs are extremely high, and most patients experience relapse after a fewdisease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistantimmortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are notreliant upon the same mechanisms as those which have been targeted). To address these limitations, aninternational task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspectsof relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a widerange of high-priority targets (74 in total) that could be modified to improve patient outcomes. For thesetargets, corresponding low-toxicity therapeutic approaches were then suggested, many of which werephytochemicals. Proposed actions on each target and all of the approaches were further reviewed forknown effects on other hallmark areas and the tumor microenvironment. Potential contrary or procar-cinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixedevidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of therelationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. Thisnovel approach has potential to be relatively inexpensive, it should help us address stages and types ofcancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for futureresearch is offered

Capabilities and governance of nanotechnology in the developing world : insights from India

Based on half a decade of interdisciplinary research and informed by multi-stakeholder insights, this book proposes options for effective and inclusive governance for nanotechnology in India. It covers a range of issues such as potential research and development (R&D) prospects, science and technology (S&T) capacities and innovation systems, issues of environment, health and safety, risk and regulatory preparedness, and prospective socio-economic and ethical repercussions. With a focus on Indian developments, as well as the accompanying regulatory challenges, the book provides insights for policy and effective multi-level governance of nanotechnology

Person-Centered Outcome Metrology

This unique collection of chapters from world experts on person-centered outcome (PCO) measures addresses the following critical questions: Can individual experiences be represented in measurements that do not reduce unique differences to meaningless uniformity? How person-centric are PCO measures? Are PCO measurements capable of delivering the kind of quality assured quantification required for high-stakes decision making? Are PCO measures likely to support improved health care delivery? Have pivotal clinical studies failed to deliver treatments for diseases because of shortcomings in the PCO measures used? Are these shortcomings primarily matters of precision and meaningfulness? Or is the lack of common languages for communicating outcomes also debilitating to quality improvement, research, and the health care economy? Three key issues form an urgent basis for further investigation. First, the numbers generated by PCO measures are increasingly used as the central dependent variables upon which high stakes decisions are made. The rising profile of PCO measures places new demands for higher quality information from scale and test construction, evaluation, selection, and interpretation. Second, PCO measurement science has well-established lessons to be learned from those who have built and established the science over many decades. Finally, the goal in making a PCO measurement is to inform outcome management. As such, it is vitally important that key stakeholders understand that, over the last half century, developments in psychometrics have refocused measurement on illuminating clinically important individual differences in the context of widely reproduced patterns of variation in health and functioning, comparable scale values for quality improvement, and practical explanatory models. This book’s audience includes anyone interested in person-centered care, including healthcare researchers and practitioners, policy makers, pharmaceutical industry representatives, clinicians, patient advocates, and metrologists. This is an open access book